Biotech Values

[DewDiligence]

RGDO addendum: The remade company, which is essentially Tobira Therapeutics plus some added cash and a public listing, could be an interesting one to watch in the NASH arena. However, I will wait for more details from SEC filings and from the conference call next week before thinking about buying.

RGDO’s big rise today (+17%) may well be justified insofar as the company had no future as a standalone entity and, absent a merger, the cash balance would have eventually dwindled to zero.